Skip to Main Content

Paper Details

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Clin Cancer Res
21
2020
CD3, CD3+, CD8+, Cisplatin, Docetaxel, NSCLC, Nintedanib, Non-Small Cell Lung Cancer, PATIENTS, cisplatin, cytotoxic CD3+CD8+ T cells, docetaxel, electrolyte abnormalities, metastatic non-small cell lung cancer, nintedanib, patient, patients, transaminitis, tumor, tumor-infiltrating T cells, tumors
Author NameAffiliation
Mei JiangThe University of Texas MD Anderson Cancer Center
Jianjun ZhangThe University of Texas MD Anderson Cancer Center
Charles LuThe University of Texas MD Anderson Cancer Center
  • 1 - 3

Datasets

Release 1.2